உலகளாவிய ஆரோக்கியம் அறிவியல் நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eyevensys Raises $12M in Series B+ Funding

Eyevensys Raises $12M in Series B+ Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

United kingdomFrance generalSouth koreaPureos bioventuresPatricia zillioxInserm transfert initiativeGlobal health sciences fundInnobio fundBoehringer ingelheim venture fundKorea investmentElectrotransfection systemGlobal health sciencesஒன்றுபட்டது கிஂக்டம்தெற்கு கொரியாஉலகளாவிய ஆரோக்கியம் அறிவியல் நிதிபோஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதி

Eyevensys Raises $12M in a Series B Plus Funding Round

Eyevensys Raises $12M in a Series B Plus Funding Round
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Soult ukpyolsiSouth koreaFrance generalUnited statesUnited kingdomWedbush pacgrowFrancine behar cohenSangwoo leePureos bioventuresPatricia zillioxJeanene timberlakeGlobal health sciences fundInserm transfert initiativeEuropean medicines agencyInnobio fundBoehringer ingelheim venture fund

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical s EndoArt® Clinical Trials Across Three Continents

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents March 15, 2021 13:05 ET | Source: Quark Venture LP Quark Venture LP Vancouver, British Columbia, CANADA VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) Quark Venture LP (Quark) and GF Securities participated in the $25 million financing of EyeYon Medical, to advance its EndoArt ® clinical trials. This investment, made through the Global Health Sciences (GHS) fund, was led by a global ophthalmology industry leader and CRCP alongside new and existing shareholders BPC, Diamond BioFund, Rimonci, Pontifax and Triventures. Quark Venture’s investment in EyeYon Medical will enable the corneal healing solutions provider to accelerate its EndoArt

United statesUnited kingdomBritish columbiaNahum fereraNeena kadabaKaley wilsonGlobal health sciences fundGlobal health sciencesEyeyon medicalDiamond biofundQuark ventureEyeyon medical boardHealth sciencesYon medicalArtificial endothelial layerQuark venture lp

Eyevensys Named to French Tech 120 Program

Press release content from Business Wire. The AP news staff was not involved in its creation. Eyevensys Named to French Tech 120 Program February 15, 2021 GMT PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 15, 2021 Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021. This government-backed program, run by La French Tech, offers support for 120 French startups considered late-stage and in a hypergrowth phase. Participating companies benefit from a variety of initiatives designed to support the needs of companies in this stage, such as unlimited access to government, public and ministry services, as well as tailored services from partner agencies. Participants will also benefit from collaboration with the French Tech 120 community, and a needs analysis that will help shape future regulations.

United kingdomFrance generalUnited statesFrancine behar cohenPureos bioventuresPatricia zillioxMarion janicGlobal health sciences fundInserm transfert initiativeEuropean medicines agencyInnobio fundBoehringer ingelheim venture fundFrench techElectrotransfection systemChief innovation officerTherapy showcase